Androgen Receptor on the Move: Boarding the Microtubule Expressway to the NucleusTHADANI-MULERO, Maria; NANUS, David M; GIANNAKAKOU, Paraskevi et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 18, pp 4611-4615, issn 0008-5472, 5 p.Article

Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancerIIDA, Katsuyuki; RONG ZHENG; RUOQIAN SHEN et al.International journal of oncology. 2012, Vol 41, Num 4, pp 1192-1198, issn 1019-6439, 7 p.Article

Inactivation of the NF2 Tumor Suppressor Protein Merlin in DU145 Prostate Cancer CellsHORIGUCHI, Akio; RONG ZHENG; RUOQIAN SHEN et al.The Prostate. 2008, Vol 68, Num 9, pp 975-984, issn 0270-4137, 10 p.Article

Renal cell carcinoma and interferon at the millenniumPASTORE, Raymond D; PFEFFER, Lawrence M; NANUS, David M et al.Cancer investigation. 2001, Vol 19, Num 3, pp 281-291, issn 0735-7907Article

Chemotherapeutic strategies for renal cell carcinomaMILOWSKY, Matthew I; NANUS, David M.Urologic clinics of North America. 2003, Vol 30, Num 3, issn 0094-0143, x, 601-609 [10 p.]Article

Activation of HIF2α in Kidney Proximal Tubule Cells Causes Abnormal Glycogen Deposition but not TumorigenesisLEIPING FU; GANG WANG; SHEVCHUK, Maria M et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 9, pp 2916-2925, issn 0008-5472, 10 p.Article

Generation of a Mouse Model of Von Hippel―Lindau Kidney Disease Leading to Renal Cancers by Expression of a Constitutively Active Mutant of HIF1αLEIPING FU; GANG WANG; SHEVCHUK, Maria M et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 21, pp 6848-6856, issn 0008-5472, 9 p.Article

Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate modelELLEN TOUMA, Sue; PERNER, Sven; RUBIN, Mark A et al.Biochemical pharmacology. 2009, Vol 78, Num 9, pp 1127-1138, issn 0006-2952, 12 p.Article

Transitional Cell Carcinoma of the Bladder: Racial and Gender Disparities in Survival (1993 to 2002), Stage and Grade (1993 to 2007)MALLIN, Katherine; DAVID, Kevin A; CARROLL, Peter R et al.The Journal of urology. 2011, Vol 185, Num 5, pp 1631-1636, issn 0022-5347, 6 p.Article

Chemosensitization of androgen-independent prostate cancer with neutral endopeptidaseSUMITOMO, Makoto; ASANO, Tomohiko; ASAKUMA, Junichi et al.Clinical cancer research. 2004, Vol 10, Num 1, pp 260-266, issn 1078-0432, 7 p., 1Article

Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C δ degradationSUMITOMO, Makoto; RUOQIAN SHEN; GOLDBERG, Jonathan S et al.Cancer research (Baltimore). 2000, Vol 60, Num 23, pp 6590-6596, issn 0008-5472Article

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancerJESKE, Stephanie; TAGAWA, Scott T; OLOWOKURE, Olugbenga et al.Urologic oncology. 2011, Vol 29, Num 6, pp 676-681, issn 1078-1439, 6 p.Article

Active chemotherapy for collecting duct carcinoma of the kidney: A case report and review of the literatureMILOWSKY, Matthew I; ROSMARIN, Alyssa; TICKOO, Satish K et al.Cancer. 2002, Vol 94, Num 1, pp 111-116, issn 0008-543XArticle

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003 : A report from the national cancer data baseDAVID, Kevin A; MILOWSKY, Matthew I; RITCHEY, Jamie et al.The Journal of urology. 2007, Vol 178, Num 2, pp 451-454, issn 0022-5347, 4 p.Article

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinomaNANUS, David M; GARINO, Alexandria; MILOWSKY, Matthew I et al.Cancer. 2004, Vol 101, Num 7, pp 1545-1551, issn 0008-543X, 7 p.Article

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II national cancer institute trialHUSSAIN, Maha H. A; MACVICAR, Gary R; CHEN, Helen et al.Journal of clinical oncology. 2007, Vol 25, Num 16, pp 2218-2224, issn 0732-183X, 7 p.Article

Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinomaRAMAN, Jay D; MONGAN, Nigel P; LIMIN LIU et al.Carcinogenesis (New York. Print). 2006, Vol 27, Num 3, pp 499-507, issn 0143-3334, 9 p.Article

Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progressionOSMAN, Iman; JIE DAI; MIKHAIL, Maryann et al.Cancer. 2006, Vol 107, Num 11, pp 2628-2636, issn 0008-543X, 9 p.Article

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerMILOWSKY, Matthew I; NANUS, David M; KOSTAKOGLU, Lale et al.Journal of clinical oncology. 2004, Vol 22, Num 13, pp 2522-2531, issn 0732-183X, 10 p.Article

Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathwaySUMITOMO, Makoto; MILOWSKY, Matthew I; RUOQIAN SHEN et al.Cancer research (Baltimore). 2001, Vol 61, Num 8, pp 3294-3298, issn 0008-5472Article

Retinoid receptor mRNA expression profiles in human bladder cancer specimensBOORJIAN, Stephen; SCHERR, Douglas S; MONGAN, Nigel P et al.International journal of oncology. 2005, Vol 26, Num 4, pp 1041-1048, issn 1019-6439, 8 p.Article

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate CancerTHADANI-MULERO, Maria; PORTELLA, Luigi; SHIHUA SUN et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 8, pp 2270-2282, issn 0008-5472, 13 p.Article

Phase II Study of Lutetium-177―Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate CancerTAGAWA, Scott T; MILOWSKY, Matthew I; SCHER, Howard I et al.Clinical cancer research (Print). 2013, Vol 19, Num 18, pp 5182-5191, issn 1078-0432, 10 p.Article

Phase 1/2 clinical trial of interferon α2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinomaBOORJIAN, Stephen A; MILOWSKY, Matthew I; NANUS, David M et al.Journal of immunotherapy (1997). 2007, Vol 30, Num 6, pp 655-662, issn 1524-9557, 8 p.Article

Phase I trial of ¹⁷⁷lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancerRANDER, Neil H; MILOWSKY, Matthew I; NANUS, David M et al.Journal of clinical oncology. 2005, Vol 23, Num 21, pp 4591-4601, issn 0732-183X, 11 p.Article